Cogent Biosciences(COGT)
Focus: Cogent Biosciences is a public biotech company focused on cellular immunotherapies for oncology and neurology, headquartered in Waltham, MA since 2007. The company operates at the clinical stage with a diversified pipeline spanning T-cell therapies, targeted small molecules, and surgical biomaterials.
Profile data last refreshed 12h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
17
Should You Work at Cogent Biosciences?
AI assessmentCogent is a clinical-stage turnaround bet: appealing if you thrive in high-risk environments with imminent binary events; risky if you seek stability or rapid career laddering.
Why Work Here
- Recent FDA NDA acceptance for bezuclastinib in Advanced Systemic Mastocytosis (Sept 2026) signals imminent first commercial milestone and revenue inflection.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ACTR T Cell Product
B Cell LymphomasClinical Trials (1)
NCT02840110Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
N/AHelp build intelligence for Cogent Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.